<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02751138</url>
  </required_header>
  <id_info>
    <org_study_id>University Hospital Ulm</org_study_id>
    <nct_id>NCT02751138</nct_id>
  </id_info>
  <brief_title>Determination of Immune Phenotype in Glioblastoma Patients</brief_title>
  <official_title>Determination of Immune Phenotype in Glioblastoma Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Ulm</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Ulm</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Glioblastoma multiforme (GBM) is the most common primary brain tumor in adults. Despite
      intensive research efforts and a multimodal management that actually consists of surgery,
      radiotherapy and chemotherapy with temozolomide, the prognosis is dismal. The aim of the
      current observational study is to determine immune phenotypes in individual patients with GBM
      at the time of diagnosis and to correlate tumor size, location (imaging), tumor properties
      (isocitrate dehydrogenase - 1 (IDH-1), o6-methylguanine-DNA-methyltransferase (MGMT),
      epidermal growth factor receptor (EGFR) mutation status, etc.) with clinical data, such as
      progression free and overall survival, Karnofsky index (progression free survival
      (PFS),overall survival (OS), Karnofsky score( KFS)), with blood immune phenotypes,
      biomarkers, and immune histochemical results of tumor infiltrating lymphocytes, macrophages,
      myeloid derived suppressor cells (MDSC), etc.. The different immunological phenotypes could
      predict a positive response to specific immunological therapeutic strategies and select the
      individual therapeutic plan for an individual GBM patient.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 1, 2016</start_date>
  <completion_date type="Anticipated">September 1, 2019</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2019</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>5 Years</target_duration>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Karnofsky performance score</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Glioblastoma Multiforme</condition>
  <arm_group>
    <arm_group_label>Isocitrate dehydrogenase - 1 mutated</arm_group_label>
    <description>Immunophenotype of Glioblastoma and correlation with outcome</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Isocitrate dehydrogenase - 1 wild type</arm_group_label>
    <description>Immunophenotype of Glioblastoma and correlation with outcome</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Surgery</intervention_name>
    <description>Tumor resection</description>
    <arm_group_label>Isocitrate dehydrogenase - 1 mutated</arm_group_label>
    <arm_group_label>Isocitrate dehydrogenase - 1 wild type</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Peripheral Blood Mononuclear Cell (PBMC), Plasma, Tumor tissue, DNA, RNA, miRNA
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Adult glioblastoma multiforme
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  adult glioblastoma multiforme

        Exclusion Criteria:

          -  pregnancy, unable to give consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Andrej Pala, MD</last_name>
    <phone>+4982219628866</phone>
    <email>andrej.pala@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Marion Schneider, Prof</last_name>
    <phone>+4973150060080</phone>
    <email>marion.schneider@uni-ulm.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Neurosurgery</name>
      <address>
        <city>Ulm</city>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Monika Deininger</last_name>
      <phone>+4982219622504</phone>
      <email>monika.deininger@bkh-guenzburg.de</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 19, 2016</study_first_submitted>
  <study_first_submitted_qc>April 25, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 26, 2016</study_first_posted>
  <last_update_submitted>October 25, 2017</last_update_submitted>
  <last_update_submitted_qc>October 25, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 27, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Ulm</investigator_affiliation>
    <investigator_full_name>Andrej Pala</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Immune phenotype</keyword>
  <keyword>Cytokines</keyword>
  <keyword>Genetic aberration</keyword>
  <keyword>Overall survival</keyword>
  <keyword>Progression free survival</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Immune phenotypes of glioma patients included and clinical follow-up</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

